Sydney-based Pharmaxis (ASX:PXS) has announced the first patient has been dosed in its Phase 1 clinical trial of an anti‐fibrotic Lysyl Oxidase (LOX) inhibitor focused on treating pancreatic cancer. …
Latest Video
New Stories
-
The COVID-19 vaccine manufacturing and supply deals
August 13, 2020 - - Latest News -
Dr Brendan Shaw: A presidential order with 'serious implications' for Australia
August 13, 2020 - - Latest News -
Circumstances, decisions and conditions driving vaccine decision
August 13, 2020 - - Latest News -
Indonesia jumps ahead with deal for late-stage vaccine
August 13, 2020 - - Latest News -
Governments move to limit product liability claims
August 13, 2020 - - Latest News -
A government that needs to be seen doing something
August 12, 2020 - - Latest News -
AZ-CSL licensing deal could be the most likely
August 12, 2020 - - Latest News